Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NVUS

Novus Therapeutics (NVUS) Stock Price, News & Analysis

Novus Therapeutics logo

About Novus Therapeutics Stock (NASDAQ:NVUS)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$3.20
$3.40
50-Day Range
$9.85
$16.50
52-Week Range
$4.50
$27.32
Volume
185,070 shs
Average Volume
78,851 shs
Market Capitalization
$4.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Remove Ads
Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVUS Stock News Headlines

Ptc Therapeutics Share Price (PTCT.US)
CAMP4 Therapeutics Corp.
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Tango Therapeutics Share Price (TNGX.US)
Vivoryon Therapeutics NV VVY
Viking Therapeutics Inc
CYT Cyteir Therapeutics, Inc.
See More Headlines

NVUS Stock Analysis - Frequently Asked Questions

Novus Therapeutics, Inc. (NASDAQ:NVUS) announced its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.64) by $3.87.
Read the conference call transcript
.

Novus Therapeutics shares reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Miragen Therapeutics (MGEN), Selecta Biosciences (SELB) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
11/16/2020
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NVUS
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$13.13 per share
Price / Book
0.25

Miscellaneous

Free Float
N/A
Market Cap
$4.62 million
Optionable
Not Optionable
Beta
2.07
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:NVUS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners